Fatal outcome from meningococcal disease - An association with meningococcal phenotype but not with reduced susceptibility to benzylpenicillin

Journal of Medical Microbiology

Volumn 51, Issue 10, 2002, Pages 855-860

  Trotter, Caroline L ^a   Fox, Andrew J ^a   Ramsay, Mary E ^a   Sadler, Francesca ^a   Gray, Stephen J ^a   Mallard, Richard ^a   Kaczmarski, Edward B ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PENICILLIN G;

ADOLESCENT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL VIRULENCE; CHILD; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; SEROTYPE; UNITED KINGDOM;

EID: 0036800930     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/0022-1317-51-10-855     Document Type: Article

References (29)

1. Sutcliffe EM, Jones DM, El-Sheikh S, Percival A. Penicillin-insensitive meningococci in the UK. Lancet 1988; i: 657-658.
2. Botha P. Penicillin-resistant Neisseria meningitidis in Southern Africa. Lancet 1988; i: 54.
3. Sáez-Nieto JA, Campos J. Penicillin-resistant strains of Neisseria meningitidis in Spain. Lancet 1988; i: 1452-1453.
4. Jackson LA, Tenover FC, Baker C et al. Prevalence of Neisseria meningitidis relatively resistant to penicillin in the United States, 1991. J Infect Dis 1994; 169: 438-441.
5. Saez-Nieto JA, Vazquez JA, Marcos C. Meningococci moderately resistant to penicillin. Lancet 1990; 336: 54.
6. The Australian Meningococcal Surveillance Programme. Annual report of the Australian Meningococcal Surveillance Programme 2000. Commun Dis Intell 2001; 25: 113-121.
7. Kaczmarksi EB, Sutcliffe E, Mallard RH. Antibiotic susceptibility data and trends for clinical isolates of Neisseria meningitidis: 1984-1994. J Infect 1996; 32: 91-92.
8. Kaczmarski EB. Meningococcal disease in England and Wales: 1995. Commun Dis Rep CDR Rev 1997; 7: R55-R59.
9. Turner PC, Southern KW, Spencer NJB, Pullen H. Treatment failure in meningococcal meningitis. Lancet 1990; 335: 732-733.
10. Bardi L, Badolati A, Corso A, Rossi MA. [Failure of the treatment with penicillin in a case of Neisseria meningitidis meningitis.] Medicina (B Aires) 1994; 54: 427-430.
11. Luaces Cubells C, Garcia Garcia JJ, Roca Martinez J, Latorre Otin CL. Clinical data in children with meningococcal meningitis in a Spanish hospital. Acta Paediatr 1997; 86: 26-29.
12. Iversen B, Aavitsland P. Meningococcal disease in Norway 1992-1995. Epidemiology and fatality. Scand J Infect Dis 1996; 28: 253-259.
13. Scholten RJPM, Bijlmer HA, Valkenburg HA, Dankert J. Patient and strain characteristics in relation to the outcome of meningococcal disease: A multivariate analysis. Epidemiol Infect 1994; 112: 115-124.
14. Spanjaard L, Bol P, de Marie S, Zanen HC. Association of meningococcal serotypes with the course of disease: Serotypes 2a and 2b in the Netherlands, 1959-1981. J Infect Dis 1987; 155: 277-282.
15. Booy R, Habibi P, Nadel S et al. Reduction in case fatality rate from meningococcal disease associated with improved healthcare delivery. Arch Dis Child 2001; 85: 386-390.
16. Thorburn K, Baines P, Thomson A, Hart CA. Mortality in severe meningococcal disease. Arch Dis Child 2001; 85: 382-385.
17. Brassier N, Lepoutre A, Guibourdenche M, Moyse C, Riou JY, Meningococcal meningitis and meningococcemia: Epidemiological study, France (1985-1991). Med Mal Infect 1995; 25: 584-592.
18. Ward J, Hanna JN, Bates JR, Selvey LA. Enhanced surveillance for meningococcal disease in Queensland in 1999. Commun Dis Intell 2000; 24: 332-335.
19. Cartwright K, Reilly S, White D, Stuart J. Early treatment with parenteral penicillin in meningococcal disease. BMJ 1992; 305: 143-147.
20. Feavers IM, Fox AJ, Gray S, Jones DM, Maiden MC. Antigenic diversity of meningococcal outer membrane protein PorA has implications for epidemiological analysis and vaccine design. Clin Diagn Lab Immunol 1996; 3: 444-450.
21. Tapsall JW, Shultz T, Limnios E et al. Surveillance of antibiotic resistance in invasive isolates of Neisseria meningitidis in Australia 1994-1999. National Neisseria Network of Australia. Pathology 2001; 33: 359-361.
22. Brown S, Riley G, Jamieson F. Neisseria meningitidis with decreased susceptibility to penicillin in Ontario, Canada 1997- 2000. Can Commun Dis Rep 2001; 27: 73-75.
23. Berrón S, Vázquez JA. Increase in moderate penicillin resistance and serogroup C in meningococcal strains isolated in Spain. Is there any relationship? Clin Infect Dis 1994; 18: 161-165.
24. Ashton FE, Ryan JA, Borczyk A, Caugant DA, Mancino L, Huang D. Emergence of a virulent clone of Neisseria meningitidis serotype 2a that is associated with meningococcal group C disease in Canada. J Clin Microbiol 1991; 29: 2489-2493.
25. Kaczmarski EB, Ragunathan PL, Marsh J, Gray SJ, Guiver M. Creating a national service for the diagnosis of meningococcal disease by polymerase chain reaction. Commun Dis Public Health 1998; 1: 54-56.
26. Hieber JP, Nelson JD. A pharmacologic evaluation of penicillin in children with purulent meningitis. N Engl J Med 1977; 297: 410-413.
27. Antignac A, Kriz P, Tzanakaki G, Alonso J-M, Taha M-K. Polymorphism of Neisseria meningitidis penA gene associated with reduced susceptibility to penicillin. J Antimicrob Che-mother 2001; 47: 285-296.
28. Maiden MCJ, Bygraves JA, Feil E et al. Multilocus sequence typing: A portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci USA 1998; 95: 3140-3145.
29. Donaldson L, Moores Y, Howe J. Chief Medical Officer, Chief nursing officer, Chief pharmacist. Introduction of Immunisation Against Group C Meningococcal Infection. Department of Health 1999. Available from www.doh.gov.uk/cmo/cmo9902.htm (March 02).